Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 26908 trials
Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder
NCT07712159
Not yet recruiting
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 102
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This multi-center, double-blind study, randomized controlled trial aims to evaluate the efficacy and safety of Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) in patients with major depressive disorder (MDD) Participants with major depressive disorder will be randomized to receive high-frequency TI-tACS(130 Hz), low-frequency TI-tACS(2Hz), or sham stimulation targeting the right amygdala. The intervention consists of 20 stimulation sessions administered over 2 weeks (twice a day for 5 consecutive days, followed by a 2-day break, and another 5 consecutive days). Clinical assessments will be conducted at baseline, during treatment, and at multiple follow-up time points up to 6 months. The primary outcome for MDD is the change from baseline in the Hamilton Depression Rating Scale (HAMD-17) at week 2. Secondary outcomes include changes in clinical symptoms, cognitive function, and safety profiles.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) — Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates a low-frequency (130HZ or 2HZ) envelope field in deep brain regions, particularly the right amygdala, through the interaction of two high-frequency currents.
  • Device: Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) — Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current.

Primary Outcomes

  • Change from baseline in the Hamilton Depression Rating Scale(HAMD-17) scores at week 2. (2 weeks(from baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-09-15
Completion: 2028-06
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Central South University
Collaborators: Second Xiangya Hospital of Central South University, Lanzhou University Second Hospital, Neuropsychiatric Institute of Fuzhou Second General Hospital, Affiliated Wuhan Mental Health Center of Huazhong University of Science and Technology, Affiliated WuTaiShan Hospital of Medical College of Yangzhou University, Xianyue Psychiatric Hospital, Xiamen
Principal Investigators:
  • Yumeng Ju, PhD (PRINCIPAL_INVESTIGATOR) - Second Xiangya Hospital of Central South University
  • Yan Zhang, PhD (STUDY_CHAIR) - Second Xiangya Hospital of Central South University
Contact Information
Study Contact:
Yumeng Ju( Associate Researcher), PhD
86+18100731091
yumeng.ju@csu.edu.cn
Lingsi Zeng, PhD Candidate
zenglsi@163.com
Interventions
  • Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) — Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates a low-frequency (130HZ or 2HZ) envelope field in deep brain regions, particularly the right amygdala, through the interaction of two high-frequency currents.
  • Device: Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) — Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 55 years (inclusive), any gender; 2. Diagnosis of a single or recurrent episode of Major Depressive Disorder (MDD) according to DSM-5 criteria, assessed by trained researchers using the Structured Clinical Interview for DSM-5 (SCID), without psychotic features; 3. HAMD-17 score ≥14; inadequate response to stable, regular antidepressant medication for at least 1 month at an adequate dose; 4. Education level: junior high school or above; adequate cognitive and language ability to understand and complete study assessments; 5. Voluntary participation with signed informed consent; ability to comply with study visits, treatment schedules, laboratory tests, and other study procedures. Exclusion Criteria: 1. History of psychiatric disorders other than MDD; 2. Pregnancy or lactation; 3. Neurologic disorders or serious systemic diseases (e.g., thyroid disease, lupus erythematosus, diabetes, hepatic or renal impairment, active infection, major trauma); 4. History of significant head injury or coma 5. Receipt of physical therapies such as electroconvulsive therapy or rTMS within the past six months before enrollment 6. Suspected or confirmed history of alcohol or substance dependence; 7. Current severe suicidal ideation or recent suicide attempt; 8. Current participation in another clinical trial or recent use of prohibited psychotropic medications; 9. Positive urine drug screening or abnormal thyroid function tests; 10. Contraindications to magnetic resonance imaging (MRI) or electroencephalography (EEG); 11. Inability to provide fully informed consent.
Behavioral Health Collaborative Care Model in an ICU Recovery Clinic
NCT07372586
Recruiting
Conditions PICS, Anxiety, Depression - Major Depres...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Survivors of critical illness are at high risk for mental health issues such as anxiety, depression, and PTSD. This single-site, randomized controlled trial at the Medical University of South Carolina will enroll 150 patients to compare outcomes between a behavioral health Collaborative Care Model (BH CoCM) and usual care (attention control). The intervention includes digital tools (Neuroflow), behavioral health coaching, and psychiatric support.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Health Collaborative Care Model — behavioral health collaborative care model in ICU recovery patients and families

Primary Outcomes

  • Depression (Enrollment to 6 months)
  • Anxiety (enrollment to six months)
  • Post-Traumatic Stress (enrollment to six months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2028-06-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: Health Resources and Services Administration (HRSA)
Principal Investigators:
  • Rita Bakhru, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Rita Bakhru, MD
8437924148
bakhru@musc.edu
Interventions
  • Behavioral: Behavioral Health Collaborative Care Model — behavioral health collaborative care model in ICU recovery patients and families
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29407 United States
Eligibility Criteria
Inclusion Criteria: \- Attendance at the MUSC ICU Recovery Clinic within 180 days of discharge from the hospital Exclusion Criteria: * ICU Admission was due to a primary addiction diagnosis (eg alcohol withdrawal or delirium tremens requiring ICU care) * Serious Mental Illness such as Schizophrenia, psychotic disorder, acute mania * Late Stage Dementia or Cognitive Impairment * Limited English or Spanish Proficiency * Lack of regular access to a computer, tablet or mobile device with internet access
The Effect of Laughter Yoga on Patients With Ankylosing Spondylitis
NCT07128264
Not yet recruiting
Conditions Ankylosing Spondylitis (AS)
Phase NA
Enrollment 60
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study will be conducted to evaluate the effects of laughter yoga on disease activity, pain, functional status, depression/anxiety/stress, and quality of life in ankylosing spondylitis patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Laughter Yoga — Laughter eliminates feelings such as hopelessness, anger, and anxiety, thereby alleviating stress, depression, and anxiety, raising the pain threshold, reducing stress, accelerating blood circulation, strengthening immunity, improving quality of life, strengthening memory, reducing tension, and relaxing muscles. Based on these positive effects, laughter yoga is a complementary treatment method that combines humor and laughter. Laughter yoga sessions will be conducted online via Microsoft Teams in a quiet and peaceful environment at home. The first 10-minute section consists of warm-up exercises (warming up and clapping). The second 10-minute section consists of deep breathing exercises that prepare the lungs for laughter. The third 10-minute section consists of childlike games that induce laughter without humor. The fourth and final 15-minute section consists of laughter exercises that enable laughter without any jokes, comedy, or humor.

Primary Outcomes

  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-08-29
Completion: 2026-04
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ataturk University
Principal Investigators:
  • Emine KIYAK, Prof.Dr. (STUDY_DIRECTOR) - Ataturk University
Contact Information
Study Contact:
Selanay UNAL, Graduate student
+905315011736
selenayunal65@gmail.com
Interventions
  • Behavioral: Laughter Yoga — Laughter eliminates feelings such as hopelessness, anger, and anxiety, thereby alleviating stress, depression, and anxiety, raising the pain threshold, reducing stress, accelerating blood circulation, strengthening immunity, improving quality of life, strengthening memory, reducing tension, and relaxing muscles. Based on these positive effects, laughter yoga is a complementary treatment method that combines humor and laughter. Laughter yoga sessions will be conducted online via Microsoft Teams in a quiet and peaceful environment at home. The first 10-minute section consists of warm-up exercises (warming up and clapping). The second 10-minute section consists of deep breathing exercises that prepare the lungs for laughter. The third 10-minute section consists of childlike games that induce laughter without humor. The fourth and final 15-minute section consists of laughter exercises that enable laughter without any jokes, comedy, or humor.
Eligibility Criteria
Inclusion Criteria: * Those diagnosed with ankylosing spondylitis, * Those who scored 10 or above on the depression scale, 8 or above on the anxiety scale, and 15 or above on the stress scale of the Depression-Anxiety-Stress Scale * Are over 18 years of age, * Have no hearing or communication problems, * Possess a smartphone, * Have no physical problems that would prevent them from performing yoga exercises (bleeding hemorrhoids, any type of hernia, persistent cough, incontinence, hypertension, major psychiatric disorders, pregnancy, flu, epilepsy, or surgery within the last 3 months, etc.) * Ankylosing spondylitis patients who volunteer to participate in the study will be included in the study sample. Exclusion Criteria: * Patients who do not participate in laughter yoga * Patients who wish to withdraw from the study
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
NCT06376734
Recruiting
Conditions Major Depressive Disorder, Obsessive-Com...
Phase PHASE2
Enrollment 180
Locations 2 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Transcranial magnetic stimulation — Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.

Primary Outcomes

  • Clustering of multiple behavioral measures (through study completion, average of 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-30
Completion: 2030-06-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Shan H Siddiqi, MD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's
Contact Information
Study Contact:
Emily Aquadro, MD
857-307-0294
expedition@mgb.org
Interventions
  • Device: Transcranial magnetic stimulation — Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
Study Locations (2 sites)
Acacia Clinics, Sunnyvale, California 94087 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-65 * English proficiency sufficient for informed consent, questionnaires/tasks, and treatment * Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5) * ≥20 on the Beck Depression Inventory for patients with MDD * ≥16 on the Beck Anxiety Inventory for patients with GAD * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia * Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis). * Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial Exclusion Criteria: * Active pregnancy as determined by a urine pregnancy test * Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder) * PTSD with active, clinically significant symptoms, as determined by clinician * Diagnosis of Schizoaffective Disorder, Bipolar Type * Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine/esketamine/ECT) * Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI * Any other TMS or MRI safety concerns identified by the clinician * Receiving or planning to receive other TMS treatments during course of participation * History of: * Neurosurgical intervention for mental illness * Moderate to severe autism spectrum disorder * Intellectual disability * Severe cognitive impairment * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis) * Untreated or insufficiently treated endocrine disorder * Eating disorders * Treatment with investigational drug or intervention during the study period * Current evidence of: * Mania or hypomania * Active suicidal ideation or a suicide attempt within the past year * Contraindications to either TMS or MRI (e.g., metallic implants, etc.). * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal * Significantly increased seizure risk as determined by a clinician * For participants with schizophrenia: * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team * Hospitalization with psychosis in the past 6 months * Positive urine drug screen for illicit substances * Existing tinnitus (ringing in the ears) * Any other condition deemed by the PI to interfere with the study or increase risk to the participant
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT04123314
Recruiting
Conditions Depressive Symptoms, Depression, Alzheim...
Phase EARLY_PHASE1
Enrollment 20
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin — Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.

Primary Outcomes

  • Change in Cornell Scale for Depression in Dementia (CSDD) score (Baseline and 1 week after second psilocybin session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2021-03-24
Completion: 2027-09-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: Council On Spiritual Practices, Heffter Research Institute
Principal Investigators:
  • Albert Garcia-Romeu, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Ian Geithner, MPS
4105505466
igeithn1@jhmi.edu
Albert Garcia-Romeu, PhD
4105501972
agarci33@jhmi.edu
Interventions
  • Drug: Psilocybin — Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
Study Locations (1 sites)
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland 21224 United States
Eligibility Criteria
Inclusion Criteria: * Must meet either A) Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria for Mild Neurocognitive Disorder due to AD or Major Neurocognitive Disorder due to AD with Mild severity (including probable), or B) meet criteria for MCI including a subjective memory complaint relative to previous functioning and confirmed by Clinical Dementia Rating (CDR) Memory score at screening of \>0.5 * Have Mini-Mental State Examination scores \>18 * Have a Montreal Cognitive Assessment score \<26. * Have Cornell Scale for Depression in Dementia (CSDD) patient score \>/= 6, or Geriatric Depression Scale-Short Form score ≥ 5, indicating at minimum a mild to moderate degree of distress. * Acetylcholinesterase inhibitors are allowed so long as the dose has been stable for \> 6 weeks. * Concurrent pharmacotherapy with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), and/or bupropion is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening. Allowable bupropion doses for participants will be ≤300mg/day. * Have a close friend or family member willing and able to serve the role of community observer / informant for data collection procedures Exclusion Criteria: * Individuals 86 years of age or older will be excluded. * Currently taking antipsychotics, monoamine oxidase (MAO) inhibitors, or antidepressant medications other than SSRIs, SNRIs, or bupropion. Allowable bupropion doses for participants will be ≤300mg/day. * Long-acting opioid pain medications (e.g. oxycodone sustained release, morphine sustained release - which are usually taken at 12 hour intervals) will be allowed if the last dose occurred at least 2 hours before psilocybin administration and the next dose was not scheduled until at least 8 hours after psilocybin administration. * Participants must agree not to take sildenafil, tadalafil, or similar medications within 72 hours of each psilocybin administration, as these medications may potentiate hypotensive reactions to psilocybin * Cardiovascular conditions: angina, a clinically significant ECG abnormality (e.g. atrial fibrillation or heart-rate corrected QT interval (QTc) \>450msec), Transient Ischemic Attack (TIA) in the last 6 months, stroke, artificial heart valves, or uncontrolled hypertension with resting blood pressure systolic \>150 or diastolic \>95 * Minimum acceptable heartrate at screening is 50 bpm unless the individual is cleared for participation by a cardiologist, in accord with the American College of Cardiology's 2018 guidelines for bradycardia * Seizure disorder * Insulin dependent diabetes mellitus * Renal disease (creatinine clearance \< 40 ml/min using the Cockcroft and Gault equation) * Baseline liver enzyme elevation \>2x the upper limit of normal * Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I Disorder * Family (i.e., 1st degree relative) history of Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I Disorder * Past-year hallucinogen use.
Model-based Electrical Brain Stimulation
NCT05327387
Recruiting
Conditions Medication Refractory Epilepsy Patients ...
Phase NA
Enrollment 25
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Neuropsychiatric disorders are a leading cause of disability worldwide with depressive disorders being one of the most disabling among them. Also, millions of patients do not respond to current medications or psychotherapy, which makes it critical to find an alternative therapy. Applying electrical stimulation at various brain targets has shown promise but there is a critical need to improve efficacy. Given inter- and intra-subject variabilities in neuropsychiatric disorders, this study aims to enable personalizing the stimulation therapy via i) tracking a patient's own symptoms based on their neural activity, and ii) a model of how their neural activity responds to stimulation therapy. The study will develop the modeling elements needed to realize a model-based personalized system for electrical brain stimulation to achieve this aim. The study will provide proof-of-concept demonstration in epilepsy patients who already have intracranial electroencephalography (iEEG) electrodes implanted for their standard clinical monitoring unrelated to this study, and who consent to being part of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.

Primary Outcomes

  • Decoded depression symptom ratings based on neural activity (5-10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-08
Completion: 2026-03-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: University of California, San Francisco, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Maryam M Shanechi, PhD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Maryam M Shanechi, PhD
213-740-1377
shanechi@usc.edu
HyeongChan Jo, PhD
hj_380@usc.edu
Interventions
  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
Study Locations (2 sites)
University of Southern California, Los Angeles, California 90089 United States
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Patients being evaluated for surgical treatment of medication refractory epilepsy and brain tumors will be studied. ONLY patients with electrodes implanted based on clinical criteria to locate their seizure focus will be studied. Most patients are healthy adults, outside of their epilepsy and/or brain tumor. * Subjects \>= 18 are only included in this study. * All patients with the above conditions and with implanted electrode arrays who are willing to participate and able to cooperate and follow research instructions will be recruited. However, analysis of research recording data will focus on those subjects with an IQ \>= 80, with no impairments of reading, naming, or articulation (to minimize confounds such as abnormal language processing that may affect their self-reporting with the questionnaire), and with no cerebral pathology affecting the cortical regions from which recordings are made. Exclusion Criteria: * Subjects \< 18 years old will be excluded from this study due to the high concordance of developmental disorders (cognitive and language-related) in pediatric epilepsies. * There will be no involvement of special classes of subjects, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations. * Patients who are unable to give informed consent due to a brain disorder will be excluded from the study, as it is very likely that they would be unable to carry out the tasks demanded by the study.
Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression
NCT07476534
Not yet recruiting
Conditions Solid Tumor Malignancies
Phase Not Applicable
Enrollment 100
Locations 0 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Identifying and validating molecular biomarkers associated with tumor-related anxiety and depression. By integrating psychological assessment data from clinical tumor patients with molecular detection results, and utilizing clinically accessible samples such as tumor tissues and sera from clinical cohorts, this study aims to clinically validate the tumor-derived proteins previously identified by our team as having potential regulatory roles. The goal is to clarify the clinical value of tumor-derived proteins as molecular biomarkers for tumor-related anxiety and depression, providing a molecular basis for early screening and risk stratification. Alternatively, it seeks to establish a tumor-related anxiety and depression risk assessment model based on the expression levels of tumor-derived proteins, offering a reference for the precise identification and targeted intervention of psychological disorders in tumor patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Clear tumor-derived protein-related tumor-related anxiety and depression molecular markers (2026.03-2026.12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2026-03-01
Completion: 2026-12-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Xinxiang Medical College
Contact Information
Study Contact:
姬 颖 华, Graduate student
03734402543
54234317@qq.com
Interventions
N/A
Eligibility Criteria
Inclusion Criteria: 1. Patients with solid tumors aged ≥18 years and an expected survival period of ≥3 months; 2. Patients who meet clinical diagnostic criteria and are pathologically/histologically confirmed as having solid tumors, including liver cancer patients (diagnosable by imaging); 3. Patients who can complete standardized stratified assessments for tumor-related anxiety and depression, and are able to cooperate with researchers in completing psychological scales such as the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS). They have not received any anti-anxiety/depression medications, professional psychological counseling, or psychiatric interventions before scale assessment; 4. Patients with clear consciousness, normal language communication, comprehension, and cognitive abilities, without a history of psychiatric disorders, and who can independently provide feedback on research-related information and cooperate with follow-up; 5. Patients who voluntarily participate in the study, fully understand the research objectives, procedures, potential risks, and benefits, and have signed a written informed consent form; 6. Patients who can cooperate in completing the required laboratory tests (complete blood count, blood biochemistry, coagulation function, etc.) and clinical data collection before and during the perioperative period to ensure the completeness of research data. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients aged \<21 years at first visit and with an expected survival period of \<3 months; 3. Patients who have previously received anti-anxiety/depression medications or professional psychological interventions; 4. Patients with a history or current diagnosis of psychiatric disorders, including schizophrenia, bipolar disorder, severe cognitive dysfunction, mental retardation, or those who cannot cooperate with SAS/SDS scale assessment or have contraindications to scale evaluation; 5. Patients with severe organ dysfunction or severe underlying diseases, including: liver failure (Child-Pugh C grade), renal failure (serum creatinine \>250 μmol/L or \>2.83 mg/dL), New York Heart Association (NYHA) Class IV heart failure, active pulmonary tuberculosis, HIV infection, etc. (to be determined); 6. Patients with contraindications to tumor tissue or blood sample collection, including coagulation disorders (INR \>1.5, platelets \<50×10⁹/L), severe bleeding tendency, or surgical specimens that cannot meet detection requirements (e.g., \>50% necrotic tissue, insufficient tissue amount); 7. Patients with emotional abnormalities due to non-tumor factors, including hyperthyroidism/hypothyroidism, severe malnutrition, chronic wasting diseases, or psychological stress disorders; 8. Patients who have undergone non-tumor-related surgical procedures, enteral/parenteral nutrition support within the past 1 month, or have clinical symptoms such as gastrointestinal mechanical obstruction, intractable vomiting, ascites, significant edema, or large pleural effusion; 9. Patients who are planned or currently using medications that may affect emotional assessment or protein expression detection during the study, including: long-term oral corticosteroids, 5-HT receptor agonists/antagonists (SSRIs, etc., even short-term use within 2 weeks before sampling is excluded), antipsychotic drugs, or gestagenic synthetic steroid derivatives (short-term inhaled/local use of steroids or intermittent use of inhaled bronchodilators are excluded); 10. Patients with incomplete clinical data, inability to cooperate with research-related follow-up and testing, or those who refuse to sign the informed consent form or have poor compliance.
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
NCT07136714
Recruiting
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 116
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing overweight or obesity. The treatment will be an add-on treatment to the patient's usual medication. The investigators hypothesize that adjunctive treatment with semaglutide, will lead to a significant improvement in mood compared to placebo in patients with MDD and overweight or obesity. The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from start to follow-up after 26 weeks. The MDI measures the extent to which symptoms of depression have been present in the past two weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c

Primary Outcomes

  • Change in depressive symptoms (From baseline to 26 weeks of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-09-11
Completion: 2027-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nordsjaellands Hospital
Principal Investigators:
  • Maj Vinberg, MD, PhD, DMSc (PRINCIPAL_INVESTIGATOR) - Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Contact Information
Study Contact:
Maj Vinberg, MD, DMSc
+ 45 38 64 32 27
maj.vinberg@regionh.dk
Christoffer Stanislaus, MD, ph.d.-student
Christoffer.stanislaus@regionh.dk
Interventions
  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c
Study Locations (1 sites)
Mental Health Centre North Zealand, Hillerød, Denmark 3400 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Informed oral and written consent. 2. Diagnosed with unipolar disorder according to the criteria of ICD10 (International Classification of Diseases, World Health Organization (WHO)) or the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association 3. Hamilton Depression Rating Scale, 17-items (HDRS-17)47 score ≥14, 4. Age 18 years to 65 years (both included) 5. Body mass index (BMI) ≥27 kg/m2 6. Able to speak and understand Danish Exclusion Criteria: 1. Any significant medical disorder or conditions that contraindicate the investigational drug, e.g., pregnancy, presence of known allergy GLP-1 receptor agonists, severe neurological disorder, on-going drug, or alcohol abuse 2. Coercive measures 3. Females of childbearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant within the next 9 months (26 weeks plus two months after discontinuation of semaglutide), or are not using contraceptives (during the whole study period) considered as highly effective (combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) intrauterine device - IUD, IUS, bilateral tubal occlusion, vasectomised partner, sexual abstinence) 4. Patients treated with corticosteroids or other hormone therapy (except oestrogens). 5. Any active substance abuse or dependence (except for nicotine) 6. Impaired hepatic function (plasma liver transaminases \>2 times upper normal limit). 7. Impaired renal function (serum creatinine \>150 μmol/l) 8. Cardiac problems defined as decompensated heart failure (NYHA class III/IV), unstable angina pectoris, and/or myocardial infarction within the last 12 months 9. Hypertension with systolic blood pressure \>180 mmHg or diastolic blood pressure \>100 mmHg 10. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase \>2 times upper normal limit). Receiving any experimental or pre-marketing drug within the last 3 months 11. Use of diabetes medication or weight-lowering pharmacotherapy e.g. semagultid within the preceding 3 months 12. Known type 1 and 2 diabetes or HbA1c\>48mmol/l 13. Suicidal behaviour as judged by the investigator and based on clinical evaluation. At all contact with patient attendance (please see Table 1) possible suicidality will be evaluatedaccording to the guidelines. If the patient is evaluated as suicidal, the person will be excluded from the study and evaluated by a senior consultant in psychiatry, who will take further action. 14. Any condition that the investigator feels would interfere with trial participation.
Nano-Learning for Improving Compliance Among Older Adults With Sarcopenia
NCT07185763
Active, positions filled
Conditions Learning; Lack of (Specific), Depression...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Empirical evidence suggests that the use of short videos is associated with decreased feelings of loneliness and social isolation, thereby reducing depression among older adults . Platforms that allow users to showcase aspects of their own lives also serve as a significant avenue for achieving "happiness in old age" and enhancing social interactions with acquaintances . Therefore, this study aims to provide robust evidence on the effectiveness of nano-learning interventions, particularly in the context of sarcopenia, where addressing physical and psychological well-being has become increasingly critical among this cohort.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Nano-Learning interventional program — AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.

Primary Outcomes

  • A Composite Physical Function (CPF) Scale (2 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2025-09-07
Completion: 2026-02-25
Eligibility
Age: 58 Years
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexandria University
Principal Investigators:
  • rasha eweida (PRINCIPAL_INVESTIGATOR) - Damanhour University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Nano-Learning interventional program — AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
Study Locations (1 sites)
Faculty of Nursing, Alexandria, 21523 Egypt
Eligibility Criteria
Inclusion Criteria: * Participants were eligible if they were 60 years or older, * had a diagnosis of sarcopenia based on a cut-off score of ≥3 of the Sarcopenia Geriatric Scale (SARCO-GS) (Rosas-Carrasco, 2023), * able to communicate effectively, and provided informed consent. Exclusion Criteria: * Exclusion criteria encompassed severe cognitive impairment, debilitating chronic conditions, or unstable medical status that could hinder participation. * Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), with a cutoff score of 25 or below used to exclude participants (Nasreddine, 2005).
Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients
NCT07651436
Recruiting
Conditions Depressive Disorders, End-stage Chronic ...
Phase NA
Enrollment 450
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Hemodialysis is a vital replacement therapy for patients with end-stage chronic kidney disease, but it imposes a heavy, demanding, and prolonged management, associated with a significant deterioration in quality of life. Hemodialysis patients are exposed to numerous physical, organizational, and social constraints, including repeated and prolonged sessions at the center, dietary and fluid restrictions, chronic fatigue, and frequent comorbidities. Therefore, depressive disorders in hemodialysis patients represent a major public health issue. The literature reports a high prevalence of depressive symptoms among hemodialysis patients, ranging from 22% to 60%, significantly higher than that observed in the general population. These disorders are associated with a significant deterioration in quality of life, increased hospitalizations, lower therapeutic adherence, an increased risk of suicide, and excess mortality. Despite these important clinical consequences, depressive disorders often remain underdiagnosed in hemodialysis. Current guidelines, including those from the Haute Autorité de Santé (HAS), emphasize the importance of regular quality of life assessments in patients with chronic kidney disease and recommend the use of validated questionnaires. However, they do not formalize a specific operational strategy for screening depressive disorders in routine hemodialysis practice, contributing to their under-evaluation. The gold standard diagnosis of depressive disorders relies on a structured psychiatric interview, which is difficult to reconcile with the organizational constraints of dialysis centers. Standardized self-assessment tools, such as the Hospital Anxiety and Depression Scale (HADS), particularly its depression subscale (HADS-D), have been widely used. The HADS-D has the advantage of excluding somatic symptoms and has been validated in hemodialysis patients. However, self-assessment relies on the patient's ability to express their subjective experience. Thus, the self-administration of standardized questionnaires in these patients is often challenging due to their age, comorbidities, fatigue, and functional limitations, often necessitating the intervention of healthcare staff. In contrast, registered nurses (IDE) working in hemodialysis possess longitudinal clinical knowledge of patients, acquired over repeated sessions, which can serve as a relevant lever for rapid and standardized screening of depressive symptoms. To date, the diagnostic performance of structured nursing hetero-evaluation remains poorly documented. The IDE-3D study aims to evaluate the ability of nurses to identify depressive symptoms in hemodialysis patients using structured tools, comparing the nursing hetero-evaluation of the HADS-D with the self-assessment conducted by the patient. It is part of a pragmatic approach aimed at improving the screening of depressive disorders in hemodialysis, structuring the care pathway, and enhancing the integration of mental…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses — Interventional study with minimal risks and constraints. The main objective is to evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses in patients receiving in-center hemodialysis, compared to reference self-assessment tools completed by the patients.

Primary Outcomes

  • The diagnostic performance of the hetero-assessment (From enrollment to the end of intervention (between one week and 2 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-26
Completion: 2028-10
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Annecy Genevois
Collaborators: GIRCI Auvergne Rhone-Alpes, SFNDT - Société Francophone de Néphrologie, Dialyse et Transplantation
Principal Investigators:
  • Cécile Herlet (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Annecy Genevois
Contact Information
Study Contact:
Alexandra Rippoz
0033 4 85522120
arippoz@ch-annecygenevois.fr
DRCI CH Annecy Genevois
drci.promotion@ch-annecygenevois.fr
Interventions
  • Other: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses — Interventional study with minimal risks and constraints. The main objective is to evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses in patients receiving in-center hemodialysis, compared to reference self-assessment tools completed by the patients.
Study Locations (2 sites)
Centre Hospitalier Annecy Genevois, Annecy, 74370 France
Centre Hospitalier Métropole Savoie, Chambéry, 73000 France
Eligibility Criteria
Inclusion Criteria: * Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate, * Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week, * Patient covered by the french national social welfare Exclusion Criteria: * Patient suffering from dementia * Pregnant or breastfeeding patient * Patient unable to understand the French language both orally and in writing, - making self-assessment impossible * Patient currently participating in another interventional research protocol or in an exclusion period from such research * Patient who has already been included in this study * Patient under guardianship, curatorship, or placed under judicial protection.
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
Conditions Bipolar Depression
Phase PHASE3
Enrollment 384
Locations 68 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.

Primary Outcomes

  • Children's Depression Rating Scale-Revised (CDRS-R) (Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-14
Completion: 2031-10-31
Eligibility
Age: 10 Years
Sex: ALL
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Intra-Cellular Therapies, Inc.
Principal Investigators:
  • Intra-Cellular Therapies, Inc. Clinical Trial (STUDY_DIRECTOR) - Intra-Cellular Therapies, Inc.
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.
Study Locations (68 sites)
Harmonex Neuroscience Research, Dothan, Alabama 36303 United States
Pillar Clinical Research, LLC, Little Rock, Arkansas 72204 United States
Advanced Research Center, Inc, Anaheim, California 92805 United States
Inland Psychiatric Medical Group Inc, Redlands, California 92373 United States
UC Davis Health System, Sacramento, California 95817 United States
University of California San Diego Medical Center, San Diego, California 92103 United States
Next Level Clinical Trials, LLC, West Covina, California 91790 United States
MCB Clinical Research Centers LLC, Colorado Springs, Colorado 80910 United States
Royal Palm Clinical Research, Fort Myers, Florida 33901 United States
United Research Institute, Hialeah, Florida 33012 United States
Eligibility Criteria
Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL); 4. Subject has a lifetime history of at least one manic or hypomanic episode. 5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration; 6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline; 7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline. Exclusion Criteria: 1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes: * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. 2. Intellectual disability based on Investigator opinion and DSM-5 criteria 3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization; 4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or 3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or 4. The patient is considered to be an imminent danger to him/herself or others.
Community Health Worker Implementation of Transdiagnostic Evidence-based Mental Health Intervention for Spanish-speaking Latine Parents
NCT07390630
Not yet recruiting
Conditions Depression, Anxiety, Traumatic Stress
Phase NA
Enrollment 52
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if it is doable for community health workers (CHWs) to deliver a mental health intervention to Spanish-speaking Latine parents experiencing anxiety, depression, and/or traumatic stress. The main questions it aims to answer are (1) Is it doable for CHWs to deliver the mental health intervention and for Latine parents to participate in the intervention, and (2) does the CHW-delivered intervention work in reducing Latine parents' mental health symptoms. Researchers will compare Latine parents receiving the intervention to Latine parents not receiving the intervention to see if the CHW-delivered intervention works to improve mental health symptoms. Participants will: * Participate in up to 14 weekly 1-hour sessions of the mental health intervention delivered by a CHW. They will be randomized to receive the intervention immediately or after a 5-month delay. * Participants will complete questionnaires about their symptoms, family and child functioning, as well as about how doable, acceptable, and appropriate they found the intervention * Participants will also complete a recorded interview about their experience in the intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Common Elements Treatment Approach (CETA) — CETA is a transdiagnostic evidence-based treatment (EBT) designed to be implemented in low-resource settings and delivered by lay providers with little to no prior mental health training (i.e., CHWs). CETA consists of 11 modules that address the most common mental health disorders, including depression, anxiety, and post-traumatic stress. Modules are based on common elements of EBT, and include topics of psychoeducation, behavioral activation, relaxation, cognitive restructuring, exposures, safety planning, and substance use reduction. Designed with non-specialists in mind, CETA materials follow a simple, concrete format, with a 1-5 page "manual" section and 1-2 page "steps sheet" for each module that includes goals, example wording, and guidance for in-session use during implementation. CETA has demonstrated effectiveness in RCTs around the world, but has yet to be examined in the US in the context of CHW implementation.

Primary Outcomes

  • Patient engagement (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Fidelity (Completed after each CETA session through study completion, over the course of approximately up to 5 months of participant participation)
  • Patient intervention retention (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient control retention (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient assessment completion (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient intervention feasibility, acceptability, & appropriateness (Patients will complete the mhIST immediately after their last intervention session)
  • Provider intervention feasibility, acceptability, & appropriateness (After approximately 2 years of intervention delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2027-02
Completion: 2029-03
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD), Sinai Urban Health Institute
Contact Information
Study Contact:
Erika L Gustafson, PhD
312-355-0626
gustafs6@uic.edu
Interventions
  • Behavioral: Common Elements Treatment Approach (CETA) — CETA is a transdiagnostic evidence-based treatment (EBT) designed to be implemented in low-resource settings and delivered by lay providers with little to no prior mental health training (i.e., CHWs). CETA consists of 11 modules that address the most common mental health disorders, including depression, anxiety, and post-traumatic stress. Modules are based on common elements of EBT, and include topics of psychoeducation, behavioral activation, relaxation, cognitive restructuring, exposures, safety planning, and substance use reduction. Designed with non-specialists in mind, CETA materials follow a simple, concrete format, with a 1-5 page "manual" section and 1-2 page "steps sheet" for each module that includes goals, example wording, and guidance for in-session use during implementation. CETA has demonstrated effectiveness in RCTs around the world, but has yet to be examined in the US in the context of CHW implementation.
Eligibility Criteria
INCLUSION criteria for PATIENT participants are: * 18 years or older * Identifies as Latine * Is a caregiver to a child 18 years or younger old living in the same household * Preference for Spanish services * Symptom scores in the moderate range for depression, anxiety, and/or PTSD (based on Computerized Adaptive Tests for Mental Health (CAT-MH)) EXCLUSION criteria for PATIENT participants: * Presence of mania symptoms in the mild range or higher (based on CAT-MH responses) * Presence of psychosis symptoms in mild range or higher (based on CAT-MH responses) * Active suicidal ideation (based on CAT-MH responses) * Depression, anxiety, or PTSD symptoms in the severe range (based on CAT-MH responses) * Currently receiving psychotherapy services
The Effects of Yoga Exercises in Overweight and Obese Women
NCT06979830
Not yet recruiting
Conditions Overweight and Obese Women
Phase NA
Enrollment 50
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Obesity has been defined by the World Health Organization (WHO) as an abnormal accumulation of fat in the body that negatively affects health and has been reported to be the most significant public health problem of the 21st century. In the late 1990s, WHO described obesity as a "global epidemic." This epidemic and its associated complications cause the death of 2.8 million adults annually. Additionally, obesity imposes a significant financial burden on countries' healthcare and social security systems. Therefore, obesity stands out as an issue that requires urgent preventive measures. Obesity is associated with various abnormalities in respiratory functions. Changes in respiratory system mechanics due to decreased lung volumes indicate a strong link between obesity and chronic respiratory diseases. Furthermore, obesity is a risk factor for conditions such as hypertension, cardiovascular diseases, and diabetes. Yoga is known to have numerous positive effects on health and can provide significant benefits, particularly in improving respiratory functions. Yoga is also an important tool for coping with stress, which can positively influence the respiratory system. It has been reported that yoga reduces the impact of stress on respiratory rate, promoting deep breathing and relaxation. Some studies on the effects of yoga on obesity have not reached significant conclusions. A study comparing the effects of Vinyasa and Hatha yoga on obesity management found that neither type had a significant effect on metabolism. These studies fail to fully explain the mechanism by which yoga affects obesity due to differences in yoga styles and their lack of standardization, variations in practice durations, and the differing characteristics of study populations. Furthermore, studies on obesity and yoga often have short intervention durations (an average of 8 weeks), with most involving 60-90 minute sessions conducted 1-2 times per week. Since longer-term studies are needed to better understand the relationship between obesity and yoga, this study aims to investigate the effects of yoga exercises on body composition, respiratory parameters, functional level, sleep quality, quality of life, and emotional state in overweight and obese women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: yoga exercises — The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4). Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught. Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study. Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was

Primary Outcomes

  • Forced Vital Capacity (FVC) (From enrollment to the end of treatment at twelve weeks)
  • Assessment of Dynamic Balance and Functional Level (Timed Up and Go Test) (From enrollment to the end of treatment at twelve weeks")
  • Body Mass Index (From enrollment to the end of treatment at twelve weeks)
  • Waist Circumference (From enrollment to the end of treatment at twelve weeks)
  • Hip Circumference (From enrollment to the end of treatment at twelve weeks)
  • Forced Expiratory Volume at One Second (FEV1) (From enrollment to the end of treatment at twelve weeks)
  • Peak Expiratory Flow (PEF) (From enrollment to the end of treatment at twelve weeks)
  • Maximum Mid-expiratory Flow 25-75% (MMEF25-75) (From enrollment to the end of treatment at twelve weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-06-01
Completion: 2025-10-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ondokuz Mayıs University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: yoga exercises — The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4). Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught. Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study. Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was
Eligibility Criteria
Inclusion Criteria: * Age between 18-65 years * Body Mass Index (BMI) ≥ 25 * Waist circumference \> 88 cm * Waist-to-hip ratio \> 0.8 * Being literate, willing to participate, and signing the informed consent form * No mental disorders * No orthopedic or neurological conditions affecting balance * No history of surgical operations in the last 6 months Exclusion Criteria: * Pregnant and breastfeeding mothers * Participants following any diet program for obesity * Individuals with syndromic or endocrine-related obesity * Participants who regularly exercise * Individuals using psychiatric medication * Participants with a medical history that would prevent them from practicing yoga * Participants with cardiovascular diseases that prevent exercise * Participants with a yoga history within the last 6 months * Individuals with any complications of obesity requiring medication, such as Type 2 diabetes or Stage 2 hypertension * Experiencing pain over 7 on the Visual Analog Scale (VAS)
The Kunshan Elderly Health Study
NCT05141565
Active, positions filled
Conditions Cardiovascular Diseases, Diabetes Mellit...
Phase Not Applicable
Enrollment 5945
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The Kunshan Elderly Health Study (KEHS) is a community-based prospective cohort study of chronic disease, mortality and associated factors among elderly adults in Kunshan, Eastern China.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No intervention

Primary Outcomes

  • Incidence of chronic diseases (Trough study completion, an average of 10 years)
  • Mortality (Trough study completion, an average of 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Active, positions filled
Start Date: 2021-05-17
Completion: 2032-12-31
Eligibility
Age: 65 Years
Sex: ALL
Volunteers: false
Enrollment: 5945 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Soochow University
Collaborators: Kunshan Center for Disease Control and Prevention, Suzhou Center for Disease Control and Prevention
Principal Investigators:
  • Hui Zuo, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Soochow University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: No intervention — No intervention
Study Locations (1 sites)
Kunshan Center for Disease Control and Prevention, Kunshan, Jiangsu 215301 China
Eligibility Criteria
Inclusion Criteria: * Locally registered-residents in Kunshan * Aged 65 years or above * Voluntary agreement to participate in the study (with written informed consent) Exclusion Criteria: * Patients with stroke, coronary heart disease or cancer * Patients with severe physical or mental illness * People unable to complete the survey
Study on the Correlation Between Metabolomics and Anxiety and Depression in Bronchiectasis
NCT07291167
Not yet recruiting
Conditions Bronchiectasis
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Bronchiectasis is a common lung disease. Approximately 20-40% of patients with bronchiectasis experience comorbid anxiety and depression. Multiple studies have now demonstrated that anxiety and depression are associated with an increased risk of disease exacerbation in these individuals. Therefore, this study aims to collect data on anxiety and depression status, disease exacerbation frequency, hospitalisation rates, and mortality among participants diagnosed with bronchiectasis. Concurrently, biological samples including blood, sputum, and stool will be obtained. Through metabolomics analysis, we will investigate the expression of anxiety and depression-related metabolic pathways and identify corresponding biomarkers to explore their role in the progression of bronchiectasis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: inapplicable — This study is observational in nature and did not involve any intervention measures.

Primary Outcomes

  • Frequency of acute exacerbations of bronchiectasis (up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2025-12-20
Completion: 2030-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Contact Information
Study Contact:
Xiaorong Wang
+86 18627195231
rong-100@163.com
Jianping Song
+86 15623201915
songjianpingxh@163.com
Interventions
  • Other: inapplicable — This study is observational in nature and did not involve any intervention measures.
Study Locations (1 sites)
Wuhan Union Hospital,China, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Participants' pulmonary imaging findings and clinical presentation met the diagnostic criteria for bronchiectasis * Clinically stable (no antibiotics or oral corticosteroids within 4 weeks prior to enrolment); * Patients who are willing to sign the consent form and participate in the study. Exclusion Criteria: * Age \<18 years * Does not meet the diagnostic criteria for bronchiectasis * Participants with cystic fibrosis or previous lung transplantation * Participants who are unable to cooperate with the study due to dysfunction of vital systems such as heart, brain, liver, and kidneys, or who are unable to participate in the study due to comorbid serious diseases * Participants with active disorders, including active tuberculosis, active allergic bronchopulmonary aspergillosis, active nontuberculous mycobacterial infection and malignancy or secondary traction bronchiectasis associated with pulmonary fibrosis * Pregnant or lactating females * Who are not able to provide informed consent or who refuse to participate in the clinical study
The Impact of Playing Tetris on Migrants' Mental Health
NCT06773338
Recruiting
Conditions Post-traumatic Stress Disorder (PTSD), A...
Phase NA
Enrollment 300
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study examines if playing Tetris prevents the development of Post-traumatic stress disorder or related anxiety and depressive symptoms. The investigators recruit 300 participants in total in Greece and in the Netherlands. The participants are immigrants who have applied for asylum at any point in the past. The participants are asked to answer three questionnaires (on Post-traumatic stress disorder, related anxiety and depressive symptoms, and post-migration living difficulties) on a recurring basis - once every 4 weeks, 12 times in total. Half of the participants (treatment group) are randomly selected to play Tetris after completing the questionnaires. Participants in the treatment group are instructed to play Tetris for at least 15 minutes while trying to remember bad things that recently happened to them. Tetris is administered at three instances and participants in the treatment group are encouraged to play Tetris in case of experiencing any traumatic events or having any intrusive memories during the course of the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.

Primary Outcomes

  • Post-traumatic stress disorder (From enrolment to the end of the study (40 weeks))
  • Anxiety and depression symptoms (From enrolment to the end of the study (40 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-17
Completion: 2025-12-07
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tilburg University
Collaborators: Stichting tot steun VCVGZ
Contact Information
Study Contact:
Mario Braakman, Prof.
+31629514366
Mario.Braakman@tilburguniversity.edu
Tihomir Sabchev, Dr.
t.y.sabchev@tilburguniversity.edu
Interventions
  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.
Study Locations (2 sites)
Upinion (online), The Hague, NL 2511 CJ Greece
Upinion/the humanity Hub, The Hague, NL 2511 CJ Netherlands
Eligibility Criteria
Inclusion Criteria: * Arabic-speaking immigrants of any gender who have applied for asylum in Greece or in the Netherlands, regardless of the outcome of their asylum application and their current residency status (rejected asylum seekers, recognized refugees, undocumented migrants). Exclusion Criteria: * Minors (under the age of 18).
Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design
NCT07721064
Not yet recruiting
Conditions Insomnia, Depression
Phase NA
Enrollment 747
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Co-occurring symptoms of insomnia and depression is very common in breast cancer survivors, and it is critical that scalable and easily accessible digital behavioral interventions are made available. Digital health interventions are scalable and accessible. Moreover, behavioral digital interventions have been shown to be effective in reducing symptoms of insomnia and depression, respectively, in breast cancer survivors, suggesting strong potential for public impact, though their potential for addressing co-occurring symptoms of insomnia/depression has not been tested. The purpose of this study is to evaluate the efficacy of a digital insomnia program and a digital mental health program in multiple ways: 1) as standalone interventions to reduce both symptoms of co-occurring insomnia and depression for breast cancer survivors; and 2) as components in adaptive behavioral treatment strategies that optimally sequence them for survivors who need additional support, resulting in a multifaceted supportive approach that is low cost, easily accessible, and highly efficient.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Digital Insomnia Program — A self-guided, fully automated, interactive, and tailored internet-based program modeled on the primary tenants of face-to-face CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relapse prevention). It is fully accessible as a web-based application via smartphones, computers, and tablets. Content is metered out over time through six "Cores". Each Core acts as a digital analog for the typical weekly sessions of face-to-face CBT for insomnia, following the same general structure: (1) Core objectives - what will be learned and why this information is important, (2) review of previous week's homework and sleep diary data, (3) new intervention material, (4) assignment of homework - treatment strategies for the coming week, and (5) a summary of the Core's main points. Users obtain access to a new Core based on a time- and event-based schedule (i.e., time since previous Core, completion of sleep diaries).
  • Behavioral: Digital Mental Health Program — A self-guided, fully automated app designed for brief, frequent check-ins to promote skill acquisition. Exercises in the app are assigned for 1 week each, and each exercise focuses on a specific mental health target (e.g., cognitive restructuring, savoring positive experiences, increasing knowledge of mental health).
  • Behavioral: Psychoeducation — An internet delivered program that includes modules containing general health information that is not specific to mental health or insomnia. Modules contain information on the topics such as exercise and heart health,. Content is primarily text-based and contains public domain health information; that is, content that is sourced primarily from US government health websites and is non-proprietary.

Primary Outcomes

  • Patient Health-Questionnaire-8 (PHQ-8) (Baseline)
  • Patient Health Questionnaire-8 (PHQ-8) (Post 18-weeks)
  • Insomnia Severity Index (ISI) (Baseline)
  • Insomnia Severity Index (ISI) (Post 18-weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-09-30
Completion: 2029-08-30
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 747 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Philip Chow, PhD
434-924-8082
pic2u@virginia.edu
Interventions
  • Behavioral: Digital Insomnia Program — A self-guided, fully automated, interactive, and tailored internet-based program modeled on the primary tenants of face-to-face CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relapse prevention). It is fully accessible as a web-based application via smartphones, computers, and tablets. Content is metered out over time through six "Cores". Each Core acts as a digital analog for the typical weekly sessions of face-to-face CBT for insomnia, following the same general structure: (1) Core objectives - what will be learned and why this information is important, (2) review of previous week's homework and sleep diary data, (3) new intervention material, (4) assignment of homework - treatment strategies for the coming week, and (5) a summary of the Core's main points. Users obtain access to a new Core based on a time- and event-based schedule (i.e., time since previous Core, completion of sleep diaries).
  • Behavioral: Digital Mental Health Program — A self-guided, fully automated app designed for brief, frequent check-ins to promote skill acquisition. Exercises in the app are assigned for 1 week each, and each exercise focuses on a specific mental health target (e.g., cognitive restructuring, savoring positive experiences, increasing knowledge of mental health).
  • Behavioral: Psychoeducation — An internet delivered program that includes modules containing general health information that is not specific to mental health or insomnia. Modules contain information on the topics such as exercise and heart health,. Content is primarily text-based and contains public domain health information; that is, content that is sourced primarily from US government health websites and is non-proprietary.
Study Locations (1 sites)
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: * (1) age ≥18 years * (2) Diagnosed with stage 0-3 breast cancer * (3) Primary treatment for cancer (i.e., chemotherapy, immunotherapy, radiation, and surgical procedures intended to remove malignant tissue) finished between 3 months to 5 years from enrollment, with the exception of adjuvant hormonal, endocrine, and immunotherapy * (4) elevated insomnia severity as measured by the Insomnia Severity Index (ISI) score ≥ 10, and elevated symptoms of depression as measured by the Patient Health Questionnaire-8 (PHQ-8) score ≥ 10 * (5) meets DSM 5 criteria for insomnia and depression. Exclusion Criteria: * (1) Current behavioral or psychological treatment for insomnia or depression * (2) a change in medication for insomnia or depression within the past 4 weeks * (3) irregular sleep schedules or shift work (i.e., usual bedtimes outside 8:00 p.m.-2:00 a.m. or arising time outside 4:00 a.m.-10:00 a.m.) * (4) mental health condition deemed to interfere with study procedures or put the participant at undue risk based on self-reported history of psychosis or bipolar disorder, or active suicidal ideation that necessitates more intense care (as indicated from the Pitt-Optimum Suicide Management Protocol) * (5) other self-reported untreated sleep disorders (i.e., obstructive sleep apnea, restless legs syndrome) * (6) no reliable internet access (e.g., home broadband, public network, personal data plan) by smartphone * (7) cannot read and speak English * (8) does not reside within the US.
Evaluation of the Effects of Aquatic Therapy on Activities of Daily Living, Walking, Balance, Posture, Pain, and Depression in Parkinson's Patients
NCT07390825
Recruiting
Conditions Parkinson Disease
Phase NA
Enrollment 42
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and postural instability, as well as various non-motor symptoms. Conventional land-based rehabilitation is standard; however, aquatherapy-utilizing water's buoyancy, hydrostatic pressure, and viscosity-offers a promising alternative to improve balance and mobility while reducing fall risks. This study aims to evaluate the effects of aquatherapy on gait, balance, posture, freezing of gait, activities of daily living (ADL), pain, and depression in Turkish PD patients. This is a prospective, single-blind, randomized controlled trial involving 42 patients at Ankara City Hospital. Participants will be divided into two groups: * Group 1 (Control): Home-based exercise program (5 days/week for 6 weeks). * Group 2 (Intervention): Home-based exercises plus supervised aquatherapy (3 sessions/week, 45 minutes each, in a 30-32°C pool). The study utilizes high-tech objective measurements and validated scales: * Gait \& Posture: Zebris Gait Analysis (spatiotemporal parameters) and Diers Formetric 4D (topographical posture analysis). * Balance: HUR-Smart Balance device and the Berg Balance Scale. * Clinical Scales: PDQ-39 (quality of life), Freezing of Gait Questionnaire, Falls Efficacy Scale, MMSE (cognitive), Beck Depression Inventory, and VAS (pain). This research is noteworthy as the first aquatherapy study among Turkish PD patients to utilize a large sample size and standardized aquatic exercise protocols. It seeks to provide a comprehensive analysis of both motor and non-motor improvements, potentially establishing aquatherapy as a superior adjunctive treatment for enhancing functional independence in Parkinson's patients. Primary hypothesis or outcome measure : Parkinson's Disease Questionnaire-39 . PDQ-39 is a patient-reported outcome measure designed to evaluate the health-related quality of life in Parkinson's patients across eight specific domains, including mobility, activities of daily living, and emotional well-being.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks

Primary Outcomes

  • Parkinson's Disease Questionnaire-39 (From enrollment to the end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-08-01
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara City Hospital Bilkent
Principal Investigators:
  • Halil Uçan, Prof. Doctor (STUDY_DIRECTOR) - Bilkent City Hospital
Contact Information
Study Contact:
Duygu Yanıktaş, MD
+905059025460
yanktasduygu@gmail.com
Interventions
  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks
Study Locations (2 sites)
Bilkent City Hospital, Çankaya, Ankara 06800 Turkey (Türkiye)
Bilkent City Hospital, Ankara, ÇANKAYA 06800 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Having a diagnosis of Idiopathic Parkinson's Disease between the ages of 40-80 and consenting to the treatment. * Being regularly followed by a neurologist and having a stable medical treatment regimen for at least 3 months. * Having a disease stage between 1-3 according to the Modified Hoehn-Yahr Staging Scale (MHY). * A score of 24 or higher on the Mini-Mental State Examination (MMSE). * Being able to verticalize independently and ambulate with or without assistance. Exclusion Criteria: * Having orthopedic, rheumatological, or non-Parkinson's neurological disorders that affect functional status. * Having a medical treatment regimen that has been modified within the last 3 months. * Presence of Atypical Parkinson's Disease. * Visual impairment. * Presence of dementia. * Decompensated cardiac or respiratory failure. * Diabetes insipidus. * Presence of systemic infection. * Impaired skin integrity or the presence of skin infections. * Increased sensitivity to inhaled steam or water chemicals. * History of epilepsy or asthma. * Urinary or fecal incontinence. * Refusal to participate in or consent to the treatment.
Narrative Nursing for Cesarean Mothers' Anxiety and Breastfeeding Confidence
NCT07272252
Recruiting
Conditions Postpartum Anxiety, Postpartum Depressio...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study tests whether a nurse-led "4-step narrative nursing" program can reduce anxiety and improve breastfeeding confidence in mothers who are having a planned or non-emergency cesarean section. What is the problem? About 30-40% of Chinese cesarean mothers feel high anxiety after surgery, and 1 in 5 is at risk for postpartum depression. Low confidence in breastfeeding is also common. What will we do? We will randomly assign 160 mothers (1:1) to either: Usual care - standard education and ward care, or Usual care plus narrative nursing - four short (10-20 min) conversations with a trained nurse: Before surgery - help the mother talk about her fears. 24-48 h after surgery - encourage her to "name" pain or worries and separate them from herself. Before discharge - guide her to find positive moments and build a "strong-mom" story. Two weeks later by phone - strengthen the new story and review feeding success. What will we measure? Main result: anxiety score at 48 h (STAI scale). Other results: depression risk, breastfeeding confidence, pain, and feeding rates up to 3 months. Possible benefits: Lower anxiety, better mood, higher breastfeeding rates. No drugs or extra procedures are involved, only talking. Risks: Minimal; some mothers may feel emotional during conversations, but nurses can pause or refer to counselling if needed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.

Primary Outcomes

  • Postpartum anxiety at 48 hours (48 hours post-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-03-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xi Huang
Collaborators: Xiamen University, Yilong People's Hospital
Contact Information
Study Contact:
X i Huang
+86-156-8090-6987
24520241154909@stu.xmu.edu.cn
Yinchun Tan
+86-152-8329-4749
2027687568@qq.com
Interventions
  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.
Study Locations (1 sites)
Yilong County Maternal and Child Health Hospital, Nanchong, Sichuan 637600 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-50 years 2. Scheduled for elective or non-emergency cesarean section at ≥37 weeks 3. Able to communicate in Mandarin and provide written informed consent 4. Expected hospital stay ≥24 h 5. Singleton pregnancy with stable maternal and neonatal condition allowing routine mother-baby contact Exclusion Criteria: 1. Severe psychiatric disorders (schizophrenia, bipolar disorder, active suicidal ideation) 2. Maternal or neonatal need for ICU/NICU admission 3. Emergency cesarean section preventing baseline assessment 4. Communication or cognitive impairment precluding interview
CET- REM (Correlating ECT Response to EEG Markers)
NCT04451135
Active, positions filled
Conditions ECT, Treatment Resistant Depression
Phase NA
Enrollment 31
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Single-center study to determine the relationship between changes in depression symptoms and electroencephalographic (EEG) patterns induced by electroconvulsive therapy (ECT)

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Electroencephalographic (EEG) — EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
  • Diagnostic Test: Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) — The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
  • Diagnostic Test: Ictal Electroencephalographic (EEG) Measurements — A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
  • Diagnostic Test: Post-Ictal Electroencephalographic (EEG) Suppression Measurements — A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.

Primary Outcomes

  • Interval change in Quick Inventory of Depressive Symptomatology-16 Item Self Report (QIDS-SR16) between ECT sessions. (Up to 8 weeks during patients ECT treatment course)
  • Duration of Central Positive Complexes during ECT treatments. (Up to 8 weeks during patients ECT treatment course)
  • Duration of PGES during ECT treatments. (Up to 8 weeks during patients ECT treatment course)
  • Density of EEG sleep spindles during non-rapid eye movement (NREM) stages N2 on evenings following ECT treatments. (Up to 8 weeks during patients ECT treatment course)
  • Slow wave activity (SWA) during N3 sleep on evenings following ECT treatments (Up to 8 weeks during patients ECT treatment course)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2020-10-09
Completion: 2027-06
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 31 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • MohammadMehdi Kafashan (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Diagnostic Test: Electroencephalographic (EEG) — EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
  • Diagnostic Test: Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) — The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
  • Diagnostic Test: Ictal Electroencephalographic (EEG) Measurements — A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
  • Diagnostic Test: Post-Ictal Electroencephalographic (EEG) Suppression Measurements — A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
Study Locations (1 sites)
Washington University School of Medicine/Barnes-Jewish Hospital, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or greater * Referral for ECT index course for treatment-resistant depression (unipolar major depressive disorder or bipolar depression), major depressive disorder with psychotic symptoms, schizophrenia or schizoaffective being treated for a depressed episode, unspecified depression Exclusion Criteria: * Schizophrenia or schizoaffective disorder not being treated for a depressed episode.